Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: Is rechallenging safe?

Harsha Prasada Lashkari, Donna Lancaster, Ayad Atra, Michael P. Champion, Mary M. Taj

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Severe hyperlipidaemia with asparaginase therapy is rare. We report six cases, four of which developed significant problems with severe hyperlipidaemia during induction therapy for ALL and lymphoblastic lymphoma. The median triglyceride level was 22.3 mmol/L and the median cholesterol level was 12.3 mmol/L. None of the patients showed signs or symptoms of pancreatitis. Three children were re-exposed with Peg asparaginase, and one with Erwinia asparaginase, without recurrence of hyperlipidaemia or other symptoms. These cases highlight the dilemma in managing such rare cases of symptomatic hypertriglyceridaemia secondary to asparaginase and steroid therapy.

Original languageEnglish
Pages (from-to)571-575
Number of pages5
JournalInternational Journal of Hematology
Volume94
Issue number6
DOIs
Publication statusPublished - 01-12-2011

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: Is rechallenging safe?'. Together they form a unique fingerprint.

  • Cite this